Raltegravir potassium (BioDeep_00000766002)
代谢物信息卡片
Raltegravir (potassium salt)
化学式: C20H20FKN6O5 (482.1116222)
中文名称: 雷特格韦钾盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
InChI: /q
描述信息
D004791 - Enzyme Inhibitors > D019429 - Integrase Inhibitors > D019428 - HIV Integrase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
同义名列表
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D07133
- PubChem: 23668479
- ChEMBL: CHEMBL518520
- MeSH: Raltegravir Potassium
- CAS: 871038-72-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Angelica Perna, Maria A Carleo, Silvia Mascolo, Alessandra Guida, Marcella Contieri, Carmine Sellitto, Eleonora Hay, Paolo De Blasiis, Angela Lucariello, Germano Guerra, Alfonso Baldi, Antonio De Luca, Paolo Maggi, Vincenzo Esposito. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
AIDS (London, England).
2023 03; 37(4):561-570. doi:
10.1097/qad.0000000000003455. [PMID: 36504092] - Cecilia M Shikuma, Thuy Le, Thao Vu Phuong, Glen M Chew, Van Vinh Chau Nguyen, Trieu Ly Vo, Chathura Siriwardhana, Dominic Chow, Hayk Ghukasyan, Nath Limpruttidham, Thomas Premeaux, Louie Mar Gangcuangco, Robert Paul, Lishomwa C Ndhlovu. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.
AIDS research and human retroviruses.
2022 06; 38(6):441-450. doi:
10.1089/aid.2021.0076. [PMID: 34861767] - Jen-Yu Hsu, Hsin-Yun Sun, Tan-Wen Hsieh, Sui-Yuan Chang, Yu-Chung Chuang, Yu-Shan Huang, Ching-Yu Hsiao, Yi-Ching Su, Wen-Chun Liu, Shu-Fang Chang, Chien-Ching Hung. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
Journal of global antimicrobial resistance.
2022 Jun; 29(?):7-16. doi:
10.1016/j.jgar.2022.02.007. [PMID: 35172201] - John R Koethe, Carlee Moser, Todd T Brown, James H Stein, Theodoros Kelesidis, Michael Dube, Judith Currier, Grace A McComsey. Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2022 03; 74(5):857-864. doi:
10.1093/cid/ciab542. [PMID: 34117756] - Hannah T Baddock, Sanja Brolih, Yuliana Yosaatmadja, Malitha Ratnaweera, Marcin Bielinski, Lonnie P Swift, Abimael Cruz-Migoni, Haitian Fan, Jeremy R Keown, Alexander P Walker, Garrett M Morris, Jonathan M Grimes, Ervin Fodor, Christopher J Schofield, Opher Gileadi, Peter J McHugh. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification.
Nucleic acids research.
2022 02; 50(3):1484-1500. doi:
10.1093/nar/gkab1303. [PMID: 35037045] - Domagoj Segregur, James Mann, Andrea Moir, Eva M Karlsson, Jennifer Dressman. Biorelevant in vitro Tools and in silico Modeling to Assess pH-Dependent Drug-drug Interactions for Salts of Weak Acids: Case Example Potassium Raltegravir.
Journal of pharmaceutical sciences.
2022 02; 111(2):517-528. doi:
10.1016/j.xphs.2021.09.037. [PMID: 34597624] - Nolwenn Hall, Clotilde Allavena, Christine Katlama, Alexandra Jobert, Jean-Michel Molina, Eric Cua, Firouzé Bani-Sadr, Laurent Hocqueloux, Claudine Duvivier, Dominique Merrien, Hitoto Hikombo, Elisabeth André-Garnier, Aurélie Gaultier, François Raffi. Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial.
AIDS research and therapy.
2022 01; 19(1):4. doi:
10.1186/s12981-022-00428-5. [PMID: 35033092] - Borja Mora-Peris, Michael R Keegan, Sujan Dilly Penchala, Jaime H Vera, Jonathan Underwood, Maryam Khan, Carolina Herrera, Dietmar Fuchs, Adriano Boasso, Saye Khoo, Alan Winston. Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial.
HIV research & clinical practice.
2021 12; 22(6):151-159. doi:
NULL. [PMID: 34743666] - Lisa M Frenkel, R Leavitt Morrison, Trevon L Fuller, Maria Isabel Gouvêa, Maria de Lourdes Benamor Teixeira, Robert W Coombs, David E Shapiro, Mark Mirochnick, Roslyn Hennessey, Kyle Whitson, Nahida Chakhtoura, Esaú C João. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Journal of acquired immune deficiency syndromes (1999).
2021 12; 88(4):361-365. doi:
10.1097/qai.0000000000002771. [PMID: 34369908] - Gwamaka Eliudi Mwasakifwa, Janaki Amin, Anthony Kelleher, Mark A Boyd. Inflammatory biomarkers and soft tissue changes among patients commencing second-line antiretroviral therapy after first-line virological failure.
AIDS (London, England).
2021 11; 35(14):2289-2298. doi:
10.1097/qad.0000000000003014. [PMID: 34224441] - Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
HIV research & clinical practice.
2021 10; 22(5):128-139. doi:
. [PMID: 34551678] - Anne-Genevieve Marcelin, Charlotte Charpentier, Pantxika Bellecave, Basma Abdi, Marie-Laure Chaix, Virginie Ferre, Stephanie Raymond, Djeneba Fofana, Laurence Bocket, Audrey Mirand, Helene Le Guillou-Guillemette, Brigitte Montes, Corinne Amiel, Coralie Pallier, Samira Fafi-Kremer, Anne De Monte, Elodie Alessandri-Gradt, Caroline Scholtes, Anne Maillard, Helene Jeulin, Magali Bouvier-Alias, Catherine Roussel, Georges Dos Santos, Anne Signori-Schmuck, Julia Dina, Sophie Vallet, Karl Stefic, Cathia Soulié, Vincent Calvez, Diane Descamps, Philippe Flandre. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
The Journal of antimicrobial chemotherapy.
2021 08; 76(9):2400-2406. doi:
10.1093/jac/dkab193. [PMID: 34100068] - Ninad S Chaudhary, Tobias Kind, Amanda L Willig, Michael S Saag, Sadeep Shrestha, Nicholas Funderburg, Howard W Wiener, E Turner Overton, Marguerite R Irvin. Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Medicine.
2021 Jul; 100(30):e26588. doi:
10.1097/md.0000000000026588. [PMID: 34397689] - Carolina Herrera, Julianne Lwanga, Ming Lee, Suna Mantori, Alieu Amara, Laura Else, Sujan Dilly Penchala, Deirdre Egan, Elizabeth Challenger, Laura Dickinson, Marta Boffito, Robin Shattock, Saye Khoo, Julie Fox. Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).
The Journal of antimicrobial chemotherapy.
2021 07; 76(8):2129-2136. doi:
10.1093/jac/dkab136. [PMID: 33993302] - Banda Marco, Herrera Cristina, Reynaga Cristhian, Rangel Sigfrido, Josue Del Angel, Angel Reyes, Prudente Isidoro. Dolutegravir in Mexico for special populations: A cost analysis perspective.
AIDS reviews.
2021 07; 23(3):126-132. doi:
10.24875/aidsrev.m21000042. [PMID: 34198310] - Nathalie De Castro, Olivier Marcy, Corine Chazallon, Eugène Messou, Serge Eholié, Jean-Baptiste N'takpe, Nilesh Bhatt, Celso Khosa, Isabel Timana Massango, Didier Laureillard, Giang Do Chau, Anaïs Domergue, Valdilea Veloso, Rodrigo Escada, Sandra Wagner Cardoso, Constance Delaugerre, Xavier Anglaret, Jean-Michel Molina, Beatriz Grinsztejn. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
The Lancet. Infectious diseases.
2021 06; 21(6):813-822. doi:
10.1016/s1473-3099(20)30869-0. [PMID: 33667406] - Xiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, Dionna J Green, Gilbert J Burckart, Tim R Cressey, Mark Mirochnick, Brookie M Best, John N van den Anker, André Dallmann. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir.
Clinical pharmacokinetics.
2021 06; 60(6):795-809. doi:
10.1007/s40262-020-00977-w. [PMID: 33527213] - Zahra Molavi, Sara Razi, Seyed Amir Mirmotalebisohi, Amirjafar Adibi, Marzieh Sameni, Farshid Karami, Vahid Niazi, Zahra Niknam, Morteza Aliashrafi, Mohammad Taheri, Soudeh Ghafouri-Fard, Shabnam Jeibouei, Soodeh Mahdian, Hakimeh Zali, Mohammad Mehdi Ranjbar, Mohsen Yazdani. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2021 Jun; 138(?):111544. doi:
10.1016/j.biopha.2021.111544. [PMID: 34311539] - Prashanth Chowdary, Shraddha Shetty, John Booth, Muhammad Arslan Khurram, Magdi Yaqoob, Ismail Heyder Mohamed. Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.
Transplant infectious disease : an official journal of the Transplantation Society.
2021 Apr; 23(2):e13500. doi:
10.1111/tid.13500. [PMID: 33174284] - Yi Zheng, Gabrielle Lui, Sana Boujaafar, Radia Aboura, Naïm Bouazza, Frantz Foissac, Jean-Marc Treluyer, Sihem Benaboud, Déborah Hirt, Inès Gana. Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2021 Mar; 196(?):113923. doi:
10.1016/j.jpba.2021.113923. [PMID: 33571728] - Takao Komasaka, Jennifer Dressman. Simulation of oral absorption from non-bioequivalent dosage forms of the salt of raltegravir, a poorly soluble acidic drug, using a physiologically based biopharmaceutical modeling (PBBM) approach.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Feb; 157(?):105630. doi:
10.1016/j.ejps.2020.105630. [PMID: 33122010] - Romain Palich, Clotilde Allavena, Gilles Peytavin, Cathia Soulie, Roland Tubiana, Laurence Weiss, Ana Montoya Ferrer, Claudine Duvivier, Olivier Bouchaud, Julie Bottero, Aurore Durand, Minh-Patrick Lê, Anne-Geneviève Marcelin, Yasmine Dudoit, Lambert Assoumou, Christine Katlama. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
The Journal of antimicrobial chemotherapy.
2021 01; 76(2):477-481. doi:
10.1093/jac/dkaa423. [PMID: 33099638] - Himanshu G Toor, Devjani I Banerjee, Soumya Lipsa Rath, Siddhi A Darji. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
European journal of pharmacology.
2021 Jan; 890(?):173720. doi:
10.1016/j.ejphar.2020.173720. [PMID: 33160938] - Farnaz Minooei, Joel R Fried, Joshua L Fuqua, Kenneth E Palmer, Jill M Steinbach-Rankins. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
International journal of nanomedicine.
2021; 16(?):1189-1206. doi:
10.2147/ijn.s287310. [PMID: 33623382] - Jennifer Gorwood, Christine Bourgeois, Valérie Pourcher, Guillaume Pourcher, Frédéric Charlotte, Matthieu Mantecon, Cindy Rose, Romain Morichon, Michael Atlan, Roger Le Grand, Delphine Desjardins, Christine Katlama, Bruno Fève, Olivier Lambotte, Jacqueline Capeau, Véronique Béréziat, Claire Lagathu. The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2020 12; 71(10):e549-e560. doi:
10.1093/cid/ciaa259. [PMID: 32166319] - Diana F Clarke, Jos Lommerse, Edward P Acosta, Mae P Cababasay, Jiajia Wang, Stephen A Spector, Anne Chain, Elizabeth Smith, Hedy Teppler, Rohan Hazra, Kat Calabrese, Bobbie Graham, Stephanie Popson, Yvonne Bryson, Mark Mirochnick. Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.
Journal of acquired immune deficiency syndromes (1999).
2020 12; 85(5):626-634. doi:
10.1097/qai.0000000000002492. [PMID: 32925360] - Purushothaman Indu, Marimuthu Ragavan Rameshkumar, Narasingam Arunagirinathan, Naif Abdullah Al-Dhabi, Mariadhas Valan Arasu, Savarimuthu Ignacimuthu. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Journal of infection and public health.
2020 Dec; 13(12):1856-1861. doi:
10.1016/j.jiph.2020.10.015. [PMID: 33168456] - Yi Zheng, Déborah Hirt, Sandrine Delmas, Gabrielle Lui, Sihem Benaboud, Jerome Lechedanec, Jean-Marc Tréluyer, Camille Chenevier-Gobeaux, Elisa Arezes, Ambre Gelley, Imane Amri, Saïk Urien, Naïm Bouazza, Frantz Foissac, Josiane Warszawski, Jade Ghosn. Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.
Antimicrobial agents and chemotherapy.
2020 09; 64(10):. doi:
10.1128/aac.00759-20. [PMID: 32661003] - Yogesh Kumar, Harvijay Singh, Chirag N Patel. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Journal of infection and public health.
2020 Sep; 13(9):1210-1223. doi:
10.1016/j.jiph.2020.06.016. [PMID: 32561274] - Milan Sencanski, Vladimir Perovic, Snezana B Pajovic, Miroslav Adzic, Slobodan Paessler, Sanja Glisic. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method.
Molecules (Basel, Switzerland).
2020 Aug; 25(17):. doi:
10.3390/molecules25173830. [PMID: 32842509] - Harry Coleman, Luke B Snell, Rebecca Simons, Sam T Douthwaite, Ming J Lee. Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV.
AIDS (London, England).
2020 07; 34(8):1258-1260. doi:
10.1097/qad.0000000000002571. [PMID: 32501852] - Cathia Soulie, Lambert Assoumou, Basma Abdi, Sophie Sayon, Thuy Nguyen, Marc-Antoine Valantin, Lydie Beniguel, Virginie Ferre, Chakib Alloui, Brigitte Montes, Véronique Avettand-Fenoel, Constance Delaugerre, Diane Descamps, Esteban Martinez, Jacques Reynes, Gilles Peytavin, Dominique Costagliola, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin. Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
The Journal of antimicrobial chemotherapy.
2020 07; 75(7):1943-1949. doi:
10.1093/jac/dkaa090. [PMID: 32259255] - Letizia Santinelli, Giancarlo Ceccarelli, Cristian Borrazzo, Luigi Celani, Paolo Pavone, Giuseppe Pietro Innocenti, Ornella Spagnolello, Caterina Fimiani, Fabrizio Ceci, Fiorella Di Sora, Ivano Mezzaroma, Claudio Maria Mastroianni, Gabriella d'Ettorre. Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort.
Expert review of anti-infective therapy.
2020 05; 18(5):485-492. doi:
10.1080/14787210.2020.1733415. [PMID: 32096433] - Esaú C João, R Leavitt Morrison, David E Shapiro, Nahida Chakhtoura, Maria Isabel S Gouvèa, Maria de Lourdes B Teixeira, Trevon L Fuller, Blandina T Mmbaga, James S Ngocho, Boniface N Njau, Avy Violari, Ruth Mathiba, Zaakirah Essack, Jose Henrique S Pilotto, Luis Felipe Moreira, Maria Jose Rolon, Pedro Cahn, Sinart Prommas, Timothy R Cressey, Kulkanya Chokephaibulkit, Peerawong Werarak, Lauren Laimon, Roslyn Hennessy, Lisa M Frenkel, Patricia Anthony, Brookie M Best, George K Siberry, Mark Mirochnick. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
The lancet. HIV.
2020 05; 7(5):e322-e331. doi:
10.1016/s2352-3018(20)30038-2. [PMID: 32386720] - Sulggi A Lee, Sushama Telwatte, Hiroyu Hatano, Angela D M Kashuba, Mackenzie L Cottrell, Rebecca Hoh, Teri J Liegler, Sophie Stephenson, Ma Somsouk, Peter W Hunt, Steven G Deeks, Steven Yukl, Radojka M Savic. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
Journal of acquired immune deficiency syndromes (1999).
2020 04; 83(5):530-537. doi:
10.1097/qai.0000000000002287. [PMID: 32168200] - Rossana Scutari, Claudia Alteri, Ilaria Vicenti, Domenico Di Carlo, Valentina Zuccaro, Francesca Incardona, Vanni Borghi, Antonia Bezenchek, Massimo Andreoni, Andrea Antinori, Carlo Federico Perno, Antonio Cascio, Andrea De Luca, Maurizio Zazzi, Maria Mercedes Santoro. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Journal of global antimicrobial resistance.
2020 03; 20(?):163-169. doi:
10.1016/j.jgar.2019.07.015. [PMID: 31330378] - Aurelio Orta-Resendiz, Roberto A Rodriguez-Diaz, Luis A Angulo-Medina, Mario Hernandez-Flores, Luis E Soto-Ramirez. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
AIDS research and therapy.
2020 02; 17(1):6. doi:
10.1186/s12981-020-0262-y. [PMID: 32041622] - Tomohiro Hosoda, Yuki Uehara, Toshio Naito. An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir.
Internal medicine (Tokyo, Japan).
2020 Jan; 59(2):285-287. doi:
10.2169/internalmedicine.3498-19. [PMID: 31534087] - Fernanda de Lima Moreira, Maria Paula Marques, Geraldo Duarte, Vera Lucia Lanchote. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2020 Jan; 177(?):112838. doi:
10.1016/j.jpba.2019.112838. [PMID: 31525573] - Charles S Venuto, Yoninah S Cramer, Susan L Rosenkranz, Mark Sulkowski, David L Wyles, Daniel E Cohen, Jeffrey Schmidt, Beverly L Alston-Smith, Gene D Morse. Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.
British journal of clinical pharmacology.
2020 01; 86(1):132-142. doi:
10.1111/bcp.14148. [PMID: 31656054] - Wassim Chehadeh, Osama Albaksami, Shaikhah Al-Shammari. Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.
Antiviral chemistry & chemotherapy.
2020 Jan; 28(?):2040206620927908. doi:
10.1177/2040206620927908. [PMID: 32434393] - Eugènia Negredo, Montse Jiménez, Jordi Puig, Cora Loste, Núria Pérez-Álvarez, Victor Urrea, Patricia Echeverría, Anna Bonjoch, Bonaventura Clotet, Julià Blanco. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
PloS one.
2020; 15(9):e0238575. doi:
10.1371/journal.pone.0238575. [PMID: 32941476] - Serge P Eholie, Raoul Moh, Aïda Benalycherif, Delphine Gabillard, Frédéric Ello, Eugène Messou, Jacques Zoungrana, Ismaël Diallo, Mouhamadou Diallo, Guillaume Bado, Mamadou Cisse, Almoustapha I Maiga, Amani Anzian, Thomas-d'Aquin Toni, Malika Congo-Ouedraogo, Coumba Toure-Kane, Moussa Seydi, Daouda K Minta, Adrien Sawadogo, Lassana Sangaré, Joseph Drabo, Sophie Karcher, Jérome Le Carrou, Laure-Amelie de Monteynard, Gilles Peytavin, Audrey Gabassi, Pierre-Marie Girard, Marie-Laure Chaix, Xavier Anglaret, Roland Landman. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
The lancet. HIV.
2019 11; 6(11):e750-e759. doi:
10.1016/s2352-3018(19)30228-0. [PMID: 31601544] - Jos Lommerse, Diana Clarke, Thomas Kerbusch, Henri Merdjan, Han Witjes, Hedy Teppler, Mark Mirochnick, Edward P Acosta, Larissa Wenning, Sharon Nachman, Anne Chain. Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.
CPT: pharmacometrics & systems pharmacology.
2019 09; 8(9):643-653. doi:
10.1002/psp4.12443. [PMID: 31215170] - Christine Katlama, Lambert Assoumou, Marc-Antoine Valantin, Cathia Soulié, Esteban Martinez, Lydie Béniguel, Olivier Bouchaud, François Raffi, Jean-Michel Molina, Soraya Fellahi, Gilles Peytavin, Anne-Geneviève Marcelin, Sami Kolta, Jacqueline Capeau, Severine Gibowski, Fanny Cardon, Jacques Reynes, Dominique Costagliola. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
The Journal of antimicrobial chemotherapy.
2019 09; 74(9):2742-2751. doi:
10.1093/jac/dkz224. [PMID: 31269208] - Beatriz Grinsztejn, Michael D Hughes, Justin Ritz, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Linda Wieclaw, Robert Gross, Catherine Godfrey, Sandra W Cardoso, Aggrey Bukuru, Mumbi Makanga, Sharlaa Faesen, Vidya Mave, Beatrice Wangari Ndege, Sandy Nerette Fontain, Wadzanai Samaneka, Rode Secours, Marije van Schalkwyk, Rosie Mngqibisa, Lerato Mohapi, Javier Valencia, Patcharaphan Sugandhavesa, Esmelda Montalban, Anchalee Avihingsanon, Breno R Santos, Nagalingeswaran Kumarasamy, Cecilia Kanyama, Robert T Schooley, John W Mellors, Carole L Wallis, Ann C Collier. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
The lancet. HIV.
2019 09; 6(9):e588-e600. doi:
10.1016/s2352-3018(19)30146-8. [PMID: 31371262] - Renato Ocampo, Désirée Vera, Marcelo Wolff. [Efectiveness and safety of switching to raltegravir-based regimen in dyslipidemic HIV-infected patients receiving antiretroviral therapy at Arriaran Foundation].
Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.
2019 Aug; 36(4):490-495. doi:
10.4067/s0716-10182019000400490. [PMID: 31859773] - Meghan Rothenberger, Krystelle Nganou-Makamdop, Cissy Kityo, Francis Ssali, Jeffrey G Chipman, Gregory J Beilman, Torfi Hoskuldsson, Jodi Anderson, Jake Jasurda, Thomas E Schmidt, Samuel P Calisto, Hope Pearson, Thomas Reimann, Caitlin David, Katherine Perkey, Peter Southern, Steve Wietgrefe, Erika Helgeson, Cavan Reilly, Ashley T Haase, Daniel C Douek, Courtney V Fletcher, Timothy W Schacker. Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues.
Journal of acquired immune deficiency syndromes (1999).
2019 07; 81(3):355-360. doi:
10.1097/qai.0000000000002026. [PMID: 31192893] - Stephanie N Liu, Jessica Bo Li Lu, Christy J W Watson, Philip Lazarus, Zeruesenay Desta, Brandon T Gufford. Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors.
Drug metabolism and disposition: the biological fate of chemicals.
2019 05; 47(5):535-544. doi:
10.1124/dmd.118.085035. [PMID: 30804050] - Antonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Antonio Di Biagio, Giulia Marchetti, Sergio Lo Caputo, Stefano Rusconi, Nicola Gianotti, Valentina Mazzotta, Giovanni Mazzarello, Andrea Costantini, Antonella Castagna, Andrea Antinori. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
The Journal of antimicrobial chemotherapy.
2019 05; 74(5):1363-1367. doi:
10.1093/jac/dky566. [PMID: 30698801] - Sebastiano Rizzardo, Massimiliano Lanzafame, Emanuela Lattuada, Damiano Bragantini, Stefano Nicolè, Leonardo Calza, Evelina Tacconelli. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
International journal of STD & AIDS.
2019 04; 30(5):467-471. doi:
10.1177/0956462418817049. [PMID: 30999834] - Minh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, Cathia Soulie, Soizic Le Mestre, Laurence Weiss, Yazdan Yazdanpanah, Jean-Michel Molina, Olivier Bouchaud, François Raffi, Jacques Reynes, Vincent Calvez, Anne-Geneviève Marcelin, Dominique Costagliola, Christine Katlama, Gilles Peytavin. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Pharmacotherapy.
2019 04; 39(4):514-520. doi:
10.1002/phar.2242. [PMID: 30815916] - Leonardo Calza, Vincenzo Colangeli, Marco Borderi, Simona Coladonato, Beatrice Tazza, Isabella Bon, Maria Carla Re, Pierluigi Viale. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2019 03; 74(3):731-738. doi:
10.1093/jac/dky507. [PMID: 30541118] - M Matignon, J-D Lelièvre, A Lahiani, K Abbassi, D Desvaux, A Diallo, M-N Peraldi, A-M Taburet, J Saillard, C Delaugerre, D Costagliola, L Assoumou, P Grimbert. Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.
HIV medicine.
2019 03; 20(3):202-213. doi:
10.1111/hiv.12700. [PMID: 30688008] - J M Llibre, A Montoliu, J M Miró, P Domingo, M Riera, J Tiraboschi, A Curran, F Homar, J Ambrosioni, N Abdulghani, L Force, J Peraire, J Casabona. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
HIV medicine.
2019 03; 20(3):237-247. doi:
10.1111/hiv.12710. [PMID: 30688007] - Pierre Gantner, Babacar Sylla, Laurence Morand-Joubert, Pierre Frange, Karine Lacombe, Marie-Aude Khuong, Claudine Duvivier, Odile Launay, Marina Karmochkine, Cédric Arvieux, Amélie Ménard, Lionel Piroth, Ana Canestri, Dominique Trias, Gilles Peytavin, Roland Landman, Jade Ghosn. 'Real life' use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.
PloS one.
2019; 14(4):e0216010. doi:
10.1371/journal.pone.0216010. [PMID: 31017957] - Sergio Barroso, Constanza Morén, Àlex González-Segura, Neus Riba, Joan A Arnaiz, Marcela Manriquez, Gemina Santana, José L Blanco, María Larousse, Montse Loncà, Elisa de Lazzari, Jaume Llopis, Josep Mallolas, Oscar Miró, Xavier Carné, Jose M Gatell, Glòria Garrabou, Esteban Martínez. Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.
PloS one.
2019; 14(5):e0216712. doi:
10.1371/journal.pone.0216712. [PMID: 31120908] - Cissy Kityo, Alexander J Szubert, Abraham Siika, Robert Heyderman, Mutsa Bwakura-Dangarembizi, Abbas Lugemwa, Shalton Mwaringa, Anna Griffiths, Immaculate Nkanya, Sheila Kabahenda, Simon Wachira, Godfrey Musoro, Chatu Rajapakse, Timothy Etyang, James Abach, Moira J Spyer, Priscilla Wavamunno, Linda Nyondo-Mipando, Ennie Chidziva, Kusum Nathoo, Nigel Klein, James Hakim, Diana M Gibb, A Sarah Walker, Sarah L Pett. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
PLoS medicine.
2018 12; 15(12):e1002706. doi:
10.1371/journal.pmed.1002706. [PMID: 30513108] - Wouter A van der Heijden, Reinout van Crevel, Philip G de Groot, Rolf T Urbanus, Hans J P M Koenen, Marjolein Bosch, Monique Keuter, Andre J van der Ven, Quirijn de Mast. A switch to a raltegravir containing regimen does not lower platelet reactivity in HIV-infected individuals.
AIDS (London, England).
2018 11; 32(17):2469-2475. doi:
10.1097/qad.0000000000001993. [PMID: 30134289] - Ana C Paim, Stacey A Rizza, Andrew D Badley, Mikel Prieto, Sandra J Taler, Pearlie P Chong, Nathan W Cummins. Transient Loss of HIV-1 DNA in an HIV-1 Positive Patient After Kidney Transplantation: A Case Report.
The American journal of medicine.
2018 10; 131(10):e423-e424. doi:
10.1016/j.amjmed.2018.04.022. [PMID: 29730357] - Sophie Matheron, Diane Descamps, Sebastien Gallien, Amel Besseghir, Pierre Sellier, Laurent Blum, Emmanuel Mortier, Charlotte Charpentier, Roland Tubiana, Florence Damond, Gilles Peytavin, Diane Ponscarme, Fideline Collin, Francoise Brun-Vezinet, Genevieve Chene. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2018 09; 67(8):1161-1167. doi:
10.1093/cid/ciy245. [PMID: 29590335] - David Moreno-Ajona, José Ramón Yuste, Paloma Martín, Jaime Gállego Pérez-Larraya. HTLV-1 myelopathy after renal transplant and antiviral prophylaxis: the need for screening.
Journal of neurovirology.
2018 08; 24(4):523-525. doi:
10.1007/s13365-018-0627-3. [PMID: 29532443] - Carlos Brites, Isabella Nóbrega, Estela Luz, Ana Gabriela Travassos, Cynthia Lorenzo, Eduardo M Netto. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.
HIV clinical trials.
2018 06; 19(3):94-100. doi:
10.1080/15284336.2018.1459343. [PMID: 29629852] - Leïla Belkhir, Carole Seguin-Devaux, Laure Elens, Caroline Pauly, Nicolas Gengler, Serge Schneider, Jean Ruelle, Vincent Haufroid, Bernard Vandercam. Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.
Scientific reports.
2018 05; 8(1):7359. doi:
10.1038/s41598-018-25803-z. [PMID: 29743555] - Mari Horikawa, Masao Toyoda, Nobumichi Saito, Moritsugu Kimura, Takako Kobayashi, Atsushi Takagi, Masafumi Fukagawa. Raltegravir-associated Diabetic Ketoacidosis in a Patient with HIV Infection: A Case Report.
The Tokai journal of experimental and clinical medicine.
2018 Apr; 43(1):19-23. doi:
". [PMID: 29637535] - Claire Pressiat, Déborah Hirt, Jean-Marc Treluyer, Yi Zheng, Philippe Morlat, Alice Naqvi, Laurent Tran, Jean-Paul Viard, Véronique Avettand-Fenoel, Christine Rouzioux, Laurence Meyer, Antoine Cheret. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
The Journal of antimicrobial chemotherapy.
2018 04; 73(4):1020-1024. doi:
10.1093/jac/dkx498. [PMID: 29365125] - Maaike Krikke, Kiki Tesselaar, Guido E L van den Berk, Sigrid A Otto, Laura H Freriks, Steven F L van Lelyveld, Frank J L Visseren, Andy I M Hoepelman, Joop E Arends. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
HIV clinical trials.
2018 04; 19(2):75-83. doi:
10.1080/15284336.2018.1455366. [PMID: 29770748] - Kiyoto Tsuchiya, Mayu Ohuchi, Naoe Yamane, Hiroaki Aikawa, Hiroyuki Gatanaga, Shinichi Oka, Akinobu Hamada. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Biomedical chromatography : BMC.
2018 Feb; 32(2):. doi:
10.1002/bmc.4058. [PMID: 28762239] - Obiageli Offor, Netanya Utay, David Reynoso, Anoma Somasunderam, Judith Currier, Jordan Lake. Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.
PloS one.
2018; 13(5):e0196395. doi:
10.1371/journal.pone.0196395. [PMID: 29746485] - Dario Cattaneo, Davide Minisci, Sara Baldelli, Cristina Mazzali, Andrea Giacomelli, Laura Milazzo, Paola Meraviglia, Chiara Resnati, Giuliano Rizzardini, Emilio Clementi, Massimo Galli, Cristina Gervasoni. Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Journal of acquired immune deficiency syndromes (1999).
2018 01; 77(1):86-92. doi:
10.1097/qai.0000000000001558. [PMID: 28961682] - Michael D Weber, Elizabeth Andrews, Heather A Prince, Craig Sykes, Elias P Rosen, Camden Bay, Nicholas J Shaheen, Ryan D Madanick, Evan S Dellon, Kristina De Paris, Julie Ae Nelson, Cynthia L Gay, Angela Dm Kashuba. Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women.
Antiviral therapy.
2018; 23(6):495-504. doi:
10.3851/imp3236. [PMID: 29714167] - Jesús Troya, Rocio Montejano, Pablo Ryan, Cristina Gómez, Mariano Matarranz, Alfonso Cabello, Francisco Vera, María Antonia Sepúlveda, Ignacio Santos, Gloria Samperiz, Pablo Bachiller, Vicente Boix, Pilar Barrufet, Miguel Cervero, José Sanz, Javier Solís, María Yllescas, Eulalia Valencia. Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
PloS one.
2018; 13(6):e0198768. doi:
10.1371/journal.pone.0198768. [PMID: 29902204] - Hiromi Ogata-Aoki, Nobuyo Higashi-Kuwata, Shin-Ichiro Hattori, Hironori Hayashi, Matthew Danish, Manabu Aoki, Chiemi Shiotsu, Yumi Hashiguchi, Akinobu Hamada, Hisataka Kobayashi, Hironobu Ihn, Seiji Okada, Hiroaki Mitsuya. Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3-/- mice transplanted with human PBMCs.
Antiviral research.
2018 01; 149(?):78-88. doi:
10.1016/j.antiviral.2017.09.003. [PMID: 28893602] - Elżbieta Jabłonowska, Piotr Pulik, Anna Kalinowska, Jacek Gąsiorowski, Miłosz Parczewski, Monika Bociąga-Jasik, Łukasz Pulik, Ewa Siwak, Kamila Wójcik. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Journal of medical virology.
2017 12; 89(12):2122-2129. doi:
10.1002/jmv.24826. [PMID: 28390164] - Minh P Lê, Linda Belarbi, Marie-Laure Chaix, Emmanuel Dulioust, Nadia Mahjoub, Dominique Salmon, Jean-Paul Viard, Claudine Duvivier, Gilles Peytavin, Odile Launay, Jade Ghosn. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
The Journal of antimicrobial chemotherapy.
2017 Nov; 72(11):3167-3171. doi:
10.1093/jac/dkx275. [PMID: 28961979] - David M Asmuth, Corbin G Thompson, Tae-Wook Chun, Zhong-Min Ma, Surinder Mann, Talia Sainz, Sergio Serrano-Villar, Netanya S Utay, Juan Carlos Garcia, Paolo Troia-Cancio, Richard B Pollard, Christopher J Miller, Alan Landay, Angela D Kashuba. Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.
The Journal of infectious diseases.
2017 10; 216(7):813-818. doi:
10.1093/infdis/jix418. [PMID: 28968888] - Alonso Heredia, Said Hassounah, Sandra Medina-Moreno, Juan C Zapata, Nhut M Le, Yingshan Han, James S Foulke, Charles Davis, Joseph Bryant, Robert R Redfield, Mark A Wainberg. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.
The Journal of antimicrobial chemotherapy.
2017 09; 72(9):2570-2573. doi:
10.1093/jac/dkx195. [PMID: 28637235] - Giordano Madeddu, Stefano Rusconi, Alessandro Cozzi-Lepri, Simona Di Giambenedetto, Stefano Bonora, Alessia Carbone, Andrea De Luca, Nicola Gianotti, Antonio Di Biagio, Andrea Antinori. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Infection.
2017 Aug; 45(4):521-528. doi:
10.1007/s15010-017-1018-z. [PMID: 28477212] - Connie J Kim, Rodney Rousseau, Sanja Huibner, Colin Kovacs, Erika Benko, Kamnoosh Shahabi, Gabor Kandel, Mario Ostrowski, Rupert Kaul. Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
AIDS (London, England).
2017 07; 31(11):1529-1534. doi:
10.1097/qad.0000000000001515. [PMID: 28463882] - Eiko Yamada, Ritsuo Takagi, Yoshinari Tanabe, Hiroshi Fujiwara, Naoki Hasegawa, Shingo Kato. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
International journal of clinical pharmacology and therapeutics.
2017 Jul; 55(7):567-570. doi:
10.5414/cp202789. [PMID: 28427498] - Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Roberto Manfredi, Marco Borderi, Nicolo' Rossi, Matteo Conti, Rita Mancini, Pierluigi Viale. Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
AIDS research and human retroviruses.
2017 07; 33(7):632-638. doi:
10.1089/aid.2016.0291. [PMID: 28088884] - Barbara Rossetti, Genny Meini, Claudia Bianco, Silvia Lamonica, Annalisa Mondi, Simone Belmonti, Iuri Fanti, Nicoletta Ciccarelli, Simona Di Giambenedetto, Maurizio Zazzi, Andrea De Luca. Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2017 06; 91(?):18-24. doi:
10.1016/j.jcv.2017.03.018. [PMID: 28395180] - Pierre Loulergue, Mansouria Merad, Romain Coriat, Michel Ducreux, David Planchard, Valérie Boige, Axel Le Cesne, Thomas M Gregory, Vianney Poinsignon, Angelo Paci, Olivier Mir. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
Investigational new drugs.
2017 04; 35(2):247-249. doi:
10.1007/s10637-016-0405-0. [PMID: 27838867] - Xia Wang, Gregory Mink, Daniel Lin, Xinyu Song, Libin Rong. Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy.
Journal of theoretical biology.
2017 03; 416(?):16-27. doi:
10.1016/j.jtbi.2016.12.015. [PMID: 28025011] - Karl Stefic, Maud Salmona, Marisa Capitao, Marion Splittgerber, Zoha Maakaroun-Vermesse, Marie-Laure Néré, Louis Bernard, Marie-Laure Chaix, Francis Barin, Constance Delaugerre. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
The Journal of antimicrobial chemotherapy.
2017 03; 72(3):850-854. doi:
10.1093/jac/dkw507. [PMID: 27999055] - James Milburn, Rachael Jones, Jeremy B Levy. Renal effects of novel antiretroviral drugs.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2017 03; 32(3):434-439. doi:
10.1093/ndt/gfw064. [PMID: 27190354] - Florin Tuluc, Sergei Spitsin, Nancy B Tustin, Jennifer B Murray, Richard Tustin, Laura A Schankel, Andrew Wiznia, Sharon Nachman, Steven D Douglas. Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.
AIDS research and human retroviruses.
2017 02; 33(2):133-142. doi:
10.1089/aid.2016.0108. [PMID: 27615375] - Letizia Marinaro, Andrea Calcagno, Diego Ripamonti, Giovanni Cenderello, Veronica Pirriatore, Laura Trentini, Bernardino Salassa, Caterina Bramato, Giancarlo Orofino, Antonio D'Avolio, Marco Rizzi, Giovanni Di Perri, Stefano Rusconi, Stefano Bonora. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2017 02; 87(?):30-36. doi:
10.1016/j.jcv.2016.11.015. [PMID: 27992788] - Theodoros Kelesidis, Thuy Tien T Tran, Todd T Brown, Carlee Moser, Heather J Ribaudo, Michael P Dube, Otto O Yang, Grace A McComsey, James H Stein, Judith S Currier. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Antiviral therapy.
2017; 22(2):113-126. doi:
10.3851/imp3093. [PMID: 27661466] - Nicholas T Funderburg, Dihua Xu, Martin P Playford, Aditya A Joshi, Adriana Andrade, Daniel R Kuritzkes, Michael M Lederman, Nehal N Mehta. Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.
Antiviral therapy.
2017; 22(1):71-75. doi:
10.3851/imp3091. [PMID: 27740536] - Paul Randell, Akil Jackson, Ana Milinkovic, Marta Boffito, Graeme Moyle. An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
Antiviral therapy.
2017; 22(2):145-151. doi:
10.3851/imp3098. [PMID: 27708251] - John M Murray, John Zaunders, Sean Emery, David A Cooper, William J Hey-Nguyen, Kersten K Koelsch, Anthony D Kelleher. HIV dynamics linked to memory CD4+ T cell homeostasis.
PloS one.
2017; 12(10):e0186101. doi:
10.1371/journal.pone.0186101. [PMID: 29049331] - Rajesh Krishna, Lilly East, Patrick Larson, Tara Siringhaus, Lisa Herpok, Crystal Bethel-Brown, Helen Manthos, John Brejda, Michael Gartner. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.
Biopharmaceutics & drug disposition.
2016 Dec; 37(9):542-549. doi:
10.1002/bdd.2045. [PMID: 27704562] - Rajesh Krishna, Lilly East, Patrick Larson, Chandni Valiathan, Kathleen Deschamps, Julie Ann Luk, Crystal Bethel-Brown, Helen Manthos, John Brejda, Michael Gartner. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.
Biopharmaceutics & drug disposition.
2016 Dec; 37(9):533-541. doi:
10.1002/bdd.2043. [PMID: 27696440] - Zuleika Michelini, Clementina Maria Galluzzo, Maria Franca Pirillo, Daniela Francisci, Anna Degli Antoni, Angela Vivarelli, Nicoletta Ladisa, Oscar Cirioni, Liliana Elena Weimer, Vincenzo Fragola, Andrea Cara, Marco Floridia, Silvia Baroncelli. HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.
Journal of medical virology.
2016 12; 88(12):2115-2124. doi:
10.1002/jmv.24581. [PMID: 27197719] - Teresa L Parsons, Mark A Marzinke. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Journal of pharmaceutical and biomedical analysis.
2016 Nov; 131(?):333-344. doi:
10.1016/j.jpba.2016.08.016. [PMID: 27632783] - Paul P Cook, Alexandra Te Stang, Lia R Walker, Shaw M Akula, Fiona J Cook. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
Southern medical journal.
2016 11; 109(11):712-717. doi:
10.14423/smj.0000000000000560. [PMID: 27812717] - Rajesh Krishna, Lilly East, Patrick Larson, Chandni Valiathan, Kristin Butterfield, Yang Teng, Martha Hernandez-Illas. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
The Journal of pharmacy and pharmacology.
2016 Nov; 68(11):1359-1365. doi:
10.1111/jphp.12632. [PMID: 27671833] - Pierre Pradat, Jacques Durant, Corinne Brochier, Mary-Anne Trabaud, Jacqueline Cottalorda-Dufayard, Jacques Izopet, François Raffi, Frédéric Lucht, Marie-Claude Gagnieu, Caroline Gatey, Christine Jacomet, Matteo Vassallo, Pierre Dellamonica, Laurent Cotte. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
The Journal of antimicrobial chemotherapy.
2016 11; 71(11):3235-3241. doi:
10.1093/jac/dkw273. [PMID: 27432606]